Arcellx agreed to merge with Gilead Sciences' cell therapy division at $115 per share in cash plus contingent value rights tied to future milestones. The transaction values Arcellx at roughly $4.2 billion on a fully diluted basis, marking a 68% premium to the thirty-day volume-weighted average price before announcement. Gilead already held approximately 22% of Arcellx through prior equity investments and collaboration agreements dating to 2022. The CVR structure ties an additional payment of up to $35 per share to regulatory approvals and commercial thresholds for imdusiran, Arcellx's lead CAR-T candidate targeting BCMA-positive multiple myeloma.

Arcellx reported Phase 1 data for imdusiran in November showing a 100% overall response rate in seventeen heavily pretreated myeloma patients, with 88% achieving complete response or better. Median progression-free survival had not been reached at twelve months. The asset competes directly with Bristol Myers Squibb's Abecma and Johnson & Johnson's Carvykti in a myeloma CAR-T market projected to exceed $6 billion by 2028. Gilead's Kite Pharma unit manufactures Yescarta and Tecartus for hematologic malignancies but lacks a marketed BCMA asset. The Arcellx platform uses a D-domain binding technology designed to reduce cytokine release syndrome and improve persistence compared to single-chain variable fragments used in first-generation products.

The structure tells you Gilead is buying proof-of-concept at clinical scale rather than waiting for pivotal data. Arcellx filed an investigational new drug application for a Phase 2 registrational study in fourth-line myeloma in December. That study will enroll 120 patients with topline data expected in the second half of 2026. Gilead accelerates its timeline to compete with Bristol and Johnson & Johnson by eighteen months compared to an internal development path. The $35 CVR implies Gilead prices the probability-weighted value of approval plus commercial ramp at roughly 30% of the upfront consideration. That discount reflects manufacturing complexity, reimbursement uncertainty, and the risk that longer follow-up reveals durability issues common to autologous cell therapies.

Allocators should watch three datapoints. First, Gilead will report Kite manufacturing capacity utilization in its March earnings call, signaling whether the Arcellx acquisition strains existing infrastructure or justifies the $450 million facility expansion announced in September. Second, the CVR milestone definitions will appear in the definitive proxy within thirty days, clarifying whether approval in relapsed/refractory myeloma triggers full payment or requires frontline indication expansion. Third, Bristol Myers Squibb and Johnson & Johnson will likely adjust pricing or access strategies for Abecma and Carvykti ahead of imdusiran's anticipated 2027 launch, compressing margins across the category.

Gilead closes the transaction in the second quarter, subject to Arcellx shareholder approval and customary regulatory clearance. The company finances the deal with $2.8 billion in cash and $1.4 billion in debt, leaving leverage at approximately 1.2x net debt to EBITDA. That positions Gilead to pursue additional tuck-in oncology acquisitions without breaching the 2.5x covenant threshold in its existing credit facility.